Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins

American Journal of Cardiology

Volumn 90, Issue 2, 2002, Pages 165-167

  Sacks, Frank M ^a,b   Alaupovic, Petar ^c   Moye, Lemuel A ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0037099484     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02444-X     Document Type: Article

References (16)

1. Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apolipoprotein B-containing lipoproteins
2. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
3. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia
4. Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate
5. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
6. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
7. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
9. Very low density lipoproteins, apolipoproteins B, CIII, and E and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) Trial
10. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
11. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
13. Comparison of statins in hypertriglyceridemia
14. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
15. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
16. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial